- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00346645
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
17 de agosto de 2026 actualizado por: Gustave Roussy, Cancer Campus, Grand Paris
A Phase II Study of Velcade® (Bortezomib) in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy
The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior chemotherapy regimen for advanced disease.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Chemotherapy for non-small-cell lung cancer (NSCLC), mainly Cisplatin-based combinations, provides a measurable but modest survival benefit for selected patients with advanced disease.
Advanced NSCLC remains largely fatal, with the positive impact of chemotherapy limited by intrinsic and acquired resistance, manifested clinically by early progression and transient responses.
Current chemotherapy regimens have limited efficacy with a magnitude of survival benefit that is still modest, and lead to significant toxicity, with many patients unable to receive this kind of treatment, even in first line setting.
There is, therefore, a great need to provide patients with less toxic agents such as the novel targeted therapies, with the potential to improve the efficacy and maintain a good quality of life.
Bortezomib, a proteasome inhibitor, has shown benefit as single agent in pretreated patients with similar or lesser toxicity compared to chemotherapy.
The current project is a phase II trial that will include 46 patients with advanced NSCLC and without prior chemotherapy.
An early tumor assessment (after 6 weeks of therapy) will be performed, combined with regular clinical and symptom assessment to allow for rapid and appropriate management of non-responding patients, with cross over to another therapy as per the investigator and patient choice.
The primary objective is efficacy of bortezomib as determined by the rate of no progression at 6 weeks.
Secondary objectives are efficacy of bortezomib as determined by objective response rate (incidence of CR and PR), disease control rate (CR, PR and stabilization), duration of disease control, duration of objective response, progression-free survival,overall survival, safety of bortezomib, rate of doublet therapy in second line.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
46
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Villejuif, Francia, 94800
- Institut Gustave Roussy
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- Histologically documented, inoperable, unresectable, incurable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) non-small cell lung cancer. (Note: Histology is the preferred method of diagnosis. However, in case only cytology is available, specimens from brushing, washing or needle aspiration etc. are acceptable for diagnosis. Sputum cytology alone is not acceptable)
- No prior chemotherapy or therapy with systemic anti-tumour therapy (e.g., monoclonal antibody therapy). Prior surgery and/or localized irradiation (palliative RT or curative RT) is permitted. Pre operative or post operative anti neo-plastic therapy is allowed if ended more than 2 years ago
- No prior exposure to agents directed at the HER axis (e.g. EGFR TK Inhibitors, Herceptin)
- Measurable disease as defined by RECIST criteria (attachment 1)
- Age 18 or greater
- ECOG performance status of 0 - 2 (attachment 2)
- Life expectancy of at least 12 weeks
- At least 4 weeks since any prior surgery or radiotherapy. Patients who, in the opinion of the investigator, have fully recovered from surgery in less than 4 weeks may also be considered for the study. Patients must have recovered (CTC < 1) from acute toxicities of any previous therapy
- Granulocyte count > 1.5 x 109/L, platelet count > 100 x 109/L and hemoglobin >8.0 g/dL
- Serum bilirubin must be < 1.5 upper limit of normal (ULN) or ≤ 5 times ULN in patients with liver metastases. SGOT (AST) and SGPT (ALT) must be < 3 x ULN.
- Serum creatinine < 1.5 ULN or creatinine clearance > 60 ml/min
- Normal serum calcium
- Able to comply with study and follow-up procedures
- For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before registration starting therapy
- Patients with reproductive potential must use effective contraception
- Written (signed) Informed Consent to participate in the study.
Exclusion Criteria:
- Any unstable systemic disease [including active infection, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 3, NYHA Classification of Cardiac Disease), myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease] or Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
- Patients are excluded if they have brain metastasis or spinal cord compression that is newly diagnosed and/or has not yet been definitively treated with surgery and/or radiation; previously diagnosed and treated CNS metastases or spinal cord compression with evidence of stable disease (clinically stable imaging) for at least 2 months is permitted
- Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the study drug or that might affect the interpretation of the results or render the subject at high risk from treatment complications
- Nursing mothers
- Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
- Neuropathy ³ Grade 2
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
|---|
|
Efficacy of VELCADE as determined by the rate of no progression at 6 weeks
|
Medidas de resultado secundarias
Medida de resultado |
|---|
|
Duración de la respuesta objetiva
|
|
Supervivencia libre de progresión (PFS)
|
|
Supervivencia global (SG)
|
|
Efficacy of VELCADE as determined by
|
|
Objective response rate (incidence of CR and PR)
|
|
Disease control rate (CR, PR and stabilization)
|
|
Duration of disease control
|
|
Safety of VELCADE
|
|
Rate of doublet therapy in second line
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Jean-Charles SORIA, MD, PhD, Gustave Roussy, Cancer Campus, Grand Paris
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de junio de 2006
Finalización primaria (Actual)
1 de mayo de 2007
Finalización del estudio (Actual)
1 de diciembre de 2007
Fechas de registro del estudio
Enviado por primera vez
29 de junio de 2006
Primero enviado que cumplió con los criterios de control de calidad
29 de junio de 2006
Publicado por primera vez (Estimado)
30 de junio de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
19 de agosto de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
17 de agosto de 2026
Última verificación
1 de agosto de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Químicos inorgánicos
- Ácidos borónicos
- Ácidos, no carboxílicos
- Ácidos
- Compuestos de boro
- Pirazinas
- Bortezomib
Otros números de identificación del estudio
- VELCADE
- CSET 1192
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .